Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)

Trial Profile

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cyclophosphamide
  • Indications Gastrointestinal stromal tumours; Leiomyosarcoma; Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms PEMBROSARC
  • Most Recent Events

    • 28 Sep 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (n=57) assessing the safety and efficacy of pembrolizumab in combination with metronomic cyclophosphamide in patients with advanced sarcomas and GIST, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top